A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing...

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Research

Background:

• Apolipoprotein E (apoE) plays a crucial role in lipid metabolism and reverse cholesterol transport.
• Dysfunctional apoE is implicated in atherosclerosis development.
• There is a need for novel therapeutic agents that mimic apoE's beneficial functions.

Purpose of the Study:

• To generate and characterize a novel human apoE-mimetic peptide, EpK.
• To evaluate EpK's ability to mediate cholesterol efflux and modulate inflammatory responses.
• To assess EpK's in vivo behavior and its effect on high-density lipoprotein (HDL) function.

Main Methods:

• Recombinant expression of EpK in Escherichia coli and purification.
• Biophysical characterization including solubility and α-helical content determination.
• In vitro lipid binding assays with 1,2-dimyristoyl(d54)-sn-glycero-3-phosphocholine.
• Cell culture studies using murine macrophages and THP-1 cells to assess cholesterol efflux and cytokine expression.
• In vivo studies in apoE(-/-) mice to determine EpK's association with HDL.

Main Results:

• EpK was successfully expressed and purified, exhibiting high solubility and increased α-helical structure upon lipid binding.
• EpK demonstrated lipid binding activity and mediated cholesterol efflux from macrophages more efficiently than apoAI and apoE3 on a mass basis.
• EpK inhibited lipopolysaccharide (LPS)-induced proinflammatory cytokine expression.
• In vivo, EpK associated with HDL, enhancing HDL's cholesterol efflux and anti-inflammatory capacities.

Conclusions:

• The novel apoE-mimetic peptide EpK exhibits potent cholesterol efflux and anti-inflammatory properties.
• EpK enhances HDL function, suggesting its potential as a therapeutic agent for atherosclerosis.
• EpK represents a promising novel biomaterial for cardiovascular disease management.